Novavax Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:3em;'>NVA</div>
NVAX -- USA Stock  

USD 221.50  18.44  7.69%

As many millenniums are trying to avoid healthcare space, it makes sense to break down Novavax a little further and try to understand its current market patterns. We are going to address the reasons why we are still confident in anticipation of a recovery. The returns on the market and returns on Novavax appear slightly correlated for the last few months. The appearance of strong basic indicators of the company suggests a short-term price swing for investors of Novavax. The upcoming quarterly report is expected on the 10th of March 2021. The stock experiences an active upward rally.
Published over three weeks ago
View all stories for Novavax | View All Stories
Should you trade Novavax (NASDAQ:NVAX) based on current technical indicators?
The company's average rating is Buy from 7 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Novavax market sentiment investors' perception of the future value of Novavax. Let us look at a few aspects of Novavax technical analysis. The company has Profit Margin (PM) of (133.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (35.49) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.35.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Novavax. In general, we focus on analyzing Novavax stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novavax's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Novavax's intrinsic value. In addition to deriving basic predictive indicators for Novavax, we also check how macroeconomic factors affect Novavax price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Novavax's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Novavax in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Novavax. Your research has to be compared to or analyzed against Novavax's peers to derive any actionable benefits. When done correctly, Novavax's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Novavax.

How does Novavax Stands against Peers?

Analyzing Novavax competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Novavax across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Novavax Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Novavax, but it might be worth checking our own buy vs. sell analysis

Sale by John Trizzino of tradable shares of Novavax

Legal trades by Novavax insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Novavax insider trading alert for sale of common stock by John Trizzino, EVP Chief Commercial Officer, on 27th of January 2021. This event was filed by Novavax Inc with SEC on 2021-01-27. Statement of changes in beneficial ownership - SEC Form 4. John Trizzino currently serves as senior vice president - commercial operations of Novavax [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Novavax Variance

Novavax has current Variance of 36.59. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance 
 = 
SUM(RET DEV)2 
 = 
36.59
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare Novavax Variance to its closest peers:
NVAX
DNLI
EARS
DYAI
DTIL
NVAX36.59133519841809
DNLI23.98
EARS2,137.59
DYAI8.36
DTIL48.62

Can Novavax build up on the current rise?

Novavax current coefficient of variation rises over 828.94. Novavax is displaying above-average volatility over the selected time horizon. Investors should scrutinize Novavax independently to ensure intended market timing strategies are aligned with expectations about Novavax volatility.

Our Final Take On Novavax

While few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Novavax may offer a potential longer-term growth to investors. To conclude, as of the 30th of January 2021, our present 30 days buy-or-sell advice on the company is Cautious Hold. We believe Novavax is overvalued with very low odds of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Novavax. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com